Compare Heron Therapeutics Inc (HRTX) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Mondaycom Ltd — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Mondaycom Ltd trades at $88.33 (market cap $3.76B). The key difference: Mondaycom Ltd is far larger — about 55.3× Heron Therapeutics Inc's market cap, and Mondaycom Ltd is more actively traded (836,200 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Mondaycom Ltd for 16 Days on average.
| HRTX | MNDY | |
|---|---|---|
Market Cap | $68.01M | $3.76B |
Volume | 1,891,941 | 836,200 |
Sector | Health | Technology |
52-Week High | $1.49 | $205.24 |
52-Week Low | $0.27 | $58.81 |
Typical Hold Time | 35 Days | 16 Days |
Enterprise Value | $174.75M | $2.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Monday.com (MNDY) is trading at $89.50, up 7.17% with strong momentum following consecutive earnings beats. The stock shows bullish technical signals with support at $86 and resistance at $90. Fundamentally, the company maintains robust revenue growth ($1.23B in 2025) and high gross margins (88.74%), though valuation multiples remain elevated with P/E at 37.69. Recent news highlights strong enterprise client growth and AI integration initiatives at the upcoming Elevate '26 conference.
The outlook remains positive with 65% analyst buy ratings and a $108.64 consensus target, representing 21% upside. Key risks include competitive pressure from Meta's enterprise push and elevated valuation sensitivity. Earnings momentum and enterprise expansion provide catalysts, but investors should monitor Q3 2026 results against the $1.37 EPS expectation for sustained growth validation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
